Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Harvard Business School
McKesson
Boehringer Ingelheim
AstraZeneca

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for PF-06650833

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for PF-06650833?

PF-06650833 is an investigational drug.

There have been 8 clinical trials for PF-06650833. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2016.

The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Hidradenitis Suppurativa. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There are three US patents protecting this investigational drug and fifty international patents.

Recent Clinical Trials for PF-06650833
TitleSponsorPhase
A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis SuppurativaPfizerPhase 2
A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTSPfizerPhase 1
Bioavailability and Food Effect Study of Two Formulations of PF-06650833PfizerPhase 1

See all PF-06650833 clinical trials

Clinical Trial Summary for PF-06650833

Top disease conditions for PF-06650833
Top clinical trial sponsors for PF-06650833

See all PF-06650833 clinical trials

US Patents for PF-06650833

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-06650833   Start Trial Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc. (New York, NY)   Start Trial
PF-06650833   Start Trial Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc. (New York, NY)   Start Trial
PF-06650833   Start Trial Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-06650833

Drugname Country Document Number Estimated Expiration Related US Patent
PF-06650833 Argentina 099955 2034-04-04   Start Trial
PF-06650833 Australia 2015242291 2034-04-04   Start Trial
PF-06650833 Canada 2944475 2034-04-04   Start Trial
PF-06650833 Chile 2016002524 2034-04-04   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Dow
Baxter
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.